Search Results

Now showing 1 - 1 of 1

Add to my favorites
Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
(BMJ, 2020) Sarnaik, A. (Amod); Fardis, M. (Maria); Kirkwood, J.M. (John M.); Whitman, E. (Eric); Pavlick, A. (Anna); Medina, T. (Theresa); Martin-Algarra, S. (Salvador); Mirgoli, M. (Mariam); Corrie, P. (Pippa); Thomas, S. (Sajeve); Lewis, K. (Karl); Wu, R. (Renee); Lutzky, J. (Jose); Kluger, H. (Harriet); Khushalani, N. (Nikhil); Hamid, O. (Omid); Curti, B. (Brendan); Olah, J. (Judit); Shi, W. (Wen); Qin, H. (Harry); Larkin, J. (James); Weber, J.S. (Jeffrey S.); DiTrapani, K. (Kelly); Chesney, J. (Jason); Takamura, T. (Toshimi)
Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies such as BRAF/MEK inhibitors (if BRAF-V600E mutated). Adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) has shown antitumor efficacy with durable responses in heavily pretreated melanoma patients. Safety and efficacy of lifileucel, a centrally manufactured cryopreserved autologous TIL therapy assessed by both investigator and an independent review committee (IRC), are presented.